Suppr超能文献

大麻素治疗阿片类药物使用障碍:有何证据?

Cannabinoids for the Treatment of Opioid Use Disorder: Where is the Evidence?

机构信息

Department of Psychiatry, Brigham and Women's Hospital, Boston, MA (JS); Harvard Medical School, Boston, MA (JS, RDW); Division of Drug and Alcohol Abuse, McLean Hospital, Belmont, MA (RDW).

出版信息

J Addict Med. 2021 Apr 1;15(2):91-92. doi: 10.1097/ADM.0000000000000711.

Abstract

With the growing public interest in the potential therapeutic benefits of cannabis and cannabinoids in the treatment of opioid use disorder (OUD), some states have now either added or proposed to add OUD as an indication for their state's medical marijuana program. However, these initiatives are based on weak evidence which at present do not support the listing of cannabis or cannabinoids as a treatment for OUD. Nevertheless, studying the potential therapeutic applications of carefully chosen components of cannabis or cannabinoids to treat specific aspects of OUD is not without scientific merit. Given the high rates of treatment discontinuation among those taking medications for OUD, interventions that further improve clinical outcomes are especially needed. The potential therapeutic applications of cannabis and cannabinoids in the treatment of OUD are worthy of further study, but it should be conducted with the same rigor that we expect of all pharmaceutical products. Until we have more research to show their efficacy, policy makers and clinicians should refrain from portraying cannabis and cannabinoids as evidence-based treatments for OUD.

摘要

随着公众对大麻和大麻素在治疗阿片类药物使用障碍(OUD)方面的潜在治疗益处的兴趣日益浓厚,现在一些州已经将 OUD 添加到或提议添加到其州的医用大麻计划中。然而,这些举措的依据是薄弱的证据,目前并不支持将大麻或大麻素列为 OUD 的治疗方法。尽管如此,研究大麻或大麻素中精心挑选的成分治疗 OUD 特定方面的潜在治疗应用并非没有科学意义。鉴于接受 OUD 药物治疗的患者中有很高的治疗中断率,特别需要进一步改善临床结果的干预措施。大麻和大麻素在治疗 OUD 方面的潜在治疗应用值得进一步研究,但应该像我们对所有药物产品一样严格进行。在我们有更多研究表明它们的疗效之前,政策制定者和临床医生不应将大麻和大麻素描绘为治疗 OUD 的循证治疗方法。

相似文献

1
Cannabinoids for the Treatment of Opioid Use Disorder: Where is the Evidence?
J Addict Med. 2021 Apr 1;15(2):91-92. doi: 10.1097/ADM.0000000000000711.
3
Cannabis and Cannabinoids for Chronic Pain.
Curr Rheumatol Rep. 2017 Oct 5;19(11):67. doi: 10.1007/s11926-017-0693-1.
5
Understanding Cannabis-Based Therapeutics in Sports Medicine.
Sports Health. 2020 Nov/Dec;12(6):540-546. doi: 10.1177/1941738120956604. Epub 2020 Sep 16.
6
Does the "Entourage Effect" in Cannabinoids Exist? A Narrative Scoping Review.
Cannabis Cannabinoid Res. 2024 Oct;9(5):1202-1216. doi: 10.1089/can.2023.0052. Epub 2023 Aug 3.
7
Medical cannabis and cannabinoids in rheumatology: where are we now?
Expert Rev Clin Immunol. 2019 Oct;15(10):1019-1032. doi: 10.1080/1744666X.2019.1665997.
9
Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Curr Neurol Neurosci Rep. 2018 Jun 19;18(8):50. doi: 10.1007/s11910-018-0859-x.

引用本文的文献

2
Cannabis donation as a harm reduction strategy: a case study.
Harm Reduct J. 2024 Mar 6;21(1):58. doi: 10.1186/s12954-024-00974-3.
3
The Therapeutic Potential of Cannabidiol in Revolutionising Opioid Use Disorder Management.
Cureus. 2023 Dec 16;15(12):e50634. doi: 10.7759/cureus.50634. eCollection 2023 Dec.
5
Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies.
Drug Alcohol Depend. 2022 Dec 1;241:109702. doi: 10.1016/j.drugalcdep.2022.109702. Epub 2022 Nov 18.
8
The prevalence and pattern of cannabis use among patients attending a methadone treatment clinic in Nairobi, Kenya.
Subst Abuse Treat Prev Policy. 2022 Feb 15;17(1):12. doi: 10.1186/s13011-022-00437-7.

本文引用的文献

1
Cannabis use during methadone maintenance treatment for opioid use disorder: a systematic review and meta-analysis.
CMAJ Open. 2019 Nov 19;7(4):E665-E673. doi: 10.9778/cmajo.20190026. Print 2019 Oct-Dec.
2
Association between medical cannabis laws and opioid overdose mortality has reversed over time.
Proc Natl Acad Sci U S A. 2019 Jun 25;116(26):12624-12626. doi: 10.1073/pnas.1903434116. Epub 2019 Jun 10.
4
Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.
Am J Addict. 2019 Jul;28(4):262-265. doi: 10.1111/ajad.12869. Epub 2019 Mar 22.
5
Should Physicians Recommend Replacing Opioids With Cannabis?
JAMA. 2019 Feb 19;321(7):639-640. doi: 10.1001/jama.2019.0077.
6
Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population.
JAMA Intern Med. 2018 May 1;178(5):667-672. doi: 10.1001/jamainternmed.2018.0266.
7
Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees.
JAMA Intern Med. 2018 May 1;178(5):673-679. doi: 10.1001/jamainternmed.2018.1007.
8
Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States.
Am J Psychiatry. 2018 Jan 1;175(1):47-53. doi: 10.1176/appi.ajp.2017.17040413. Epub 2017 Sep 26.
9
Cannabis: An Overview of its Adverse Acute and Chronic Effects and its Implications.
Curr Drug Abuse Rev. 2017;10(1):6-18. doi: 10.2174/1874473710666170712113042.
10
The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.
Am J Psychiatry. 2017 Aug 1;174(8):738-747. doi: 10.1176/appi.ajp.2016.16070792. Epub 2016 Dec 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验